Remdesivir is an antiviral drug designed to treat infectious diseases such as Ebola and SARS. It has not been approved by any drug regulator in the world, but China is beginning clinical trials in humans to determine if it can treat the coronavirus that has killed 427 people and infected more than 20,000.
It will be tested by a medical team from the China-Japan Friendship Hospital in Beijing, and the trial will take place in central Wuhan, where the outbreak started, Bloomberg reported.
Remdesivir will be given to as many as 270 patients with mild to moderate pneumonia caused by the coronavirus.
The first U.S. patient infected with the virus saw his pneumonia improve after he was given remdesivir, Bloomberg reported, but it may have been unrelated to the drug.
Remdesivir is the best hope for treating the virus at the time, as it could take months for any vaccine to be available for human trials, according to Bloomberg.
Read the full article here.
More articles on pharmacy:
Overburdened pharmacists at top retail chains say they worry about patient safety
OptumRx’s drug trends to watch in 2020: 5 things to know
AmerisourceBergen closes PharMEDium unit, cuts 165 job
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
